ログイン

SNS

SNS
91問 • 1年前
  • Quinn Karylle Fuentes
  • 通報

    問題一覧

  • 1

    What are the receptors of sympathetic

    Alpha, Beta, Dopamine

  • 2

    It has the property of adjusting in response to stressful situations such as trauma, fear, hypoglycemia, cold or exercise.

    Sympathetic nervous system.

  • 3

    The endogenous neurotransmitters contain three required structural features. What are those transmitter

    Catechol nucleus, a,b- hydroxy group, Nitrogen substituents.

  • 4

    Ortho hydroxybenzene

    Catechol 1& 2

  • 5

    Meta hydroxybenzene

    Resorcino 1 & 3

  • 6

    Para hydroxybenzene

    hydroquinone 1 & 4

  • 7

    The primary neurotransmitter of postganglionic sympathetic adrenergic nerves.

    Norepinephrine.

  • 8

    Synthesized inside nerve axon in the adrenal medulla and stored within vesicles. It is released by the nerve when an action potential travels down the nerve.

    Norepinephrine.

  • 9

    Receptors= Gq linked

    Alpha 1

  • 10

    Receptors= Gi linked

    Alpha 2

  • 11

    Exert negative feedback leading to decrease in the synthesis & release of NE

    Alpha 2

  • 12

    (+) inotropism, dromotropism, chronotropism

    Beta 1

  • 13

    The increase in cAMP levels in structures with beta2 receptors on them will lead to smooth muscle relaxation but skeletal muscle contraction.

    Beta 2

  • 14

    modulation of motor activity, behavior, mood & thought process Induce vomiting

    Dopamine 2-4

  • 15

    Gs linked

    Dopamine 1

  • 16

    like family receptors is coupled to the G protein Gi, which directly inhibits the formation of cAMP by inhibiting the enzyme adenylate cyclase

    Dopamine 2-4

  • 17

    Receptors of catecholamines are example of

    Type 2

  • 18

    Drugs that mimic the action of epinephrine or norepinephrine.

    Adrenoceptor Agonists

  • 19

    What are under Nonselective

    Epinephrine, Norepinephrine, Dopamine, Isoproterenol

  • 20

    What are under selective

    ALPHA 1 agonists, ALPHA 2 agonists, BETA 1 agonists, BETA 2 agonists, DOPAMINE 1 agonists

  • 21

    Binds directly to the receptor

    Direct acting.

  • 22

    Increase concentration of catecholamines in the synaptic cleft

    Indirect acting.

  • 23

    CNS centered effects

    Centrally acting

  • 24

    What are under increase release

    Tyramine, Ephedrine, Angiotensin II, Amphetamine

  • 25

    What are under inhibit re uptake

    TCAs, Cocaine, Reboxitine

  • 26

    What are under centrally acting

    Phenylpropanolamine, Amphetamine, Methylphenidate, Phentermine, Modafinil

  • 27

    considered as the parent compound from which sympathomimetic drugs are derived.

    Phenylethylamine.

  • 28

    consists of benzene ring with an ethylamine side chain

    Phenylethylamine.

  • 29

    consists of benzene ring with an ethylamine side chain

    Norepinephrine.

  • 30

    stimulates α1 , β1 and β2

    Epinephrine

  • 31

    stimulates β1 and β2

    Isoproterenol.

  • 32

    Methyl substitution on NE, yielding Epi, enhances activity at β2 receptors. ↑ β-receptor activity. The larger the substituent on the amino group, the lower the activity at α-receptor.

    Terminal amino group.

  • 33

    Substitution of OH group on benzene ring increases maximal α & β activity

    Benzene ring.

  • 34

    INACTIVATED BY COMT, cannot be given orally polar (Poor CNS penetration)

    With OH (at 3 and 4) catecholamines

  • 35

    not inactivated by COMT, can be given orally, non polar (CNS penetration)

    Without OH (at 3 and 4) non catecholamines

  • 36

    Dec. metabolism by monoamine oxidase (MAO).

    Alpha carbon.

  • 37

    Give example of alpha carbon.

    Ephedrine, Amphetamine

  • 38

    Substitution of OH group will become a direct-acting agonists. β-hydroxyl group.

    Beta carbon.

  • 39

    Ephedrine, Phenylephrine and Amphetamine which of these are non catecholamines

    All of them

  • 40

    Ephedrine, Phenylephrine and Amphetamine which of these are resistant to MAO metabolism

    Amphetamine, Ephedrine

  • 41

    Ephedrine, Phenylephrine and Amphetamine which of these are direct acting agonist

    Ephedrine, Phenylephrine

  • 42

    Ephedrine, Phenylephrine and Amphetamine which of these are direct acting agonist

    Ephedrine, Phenylephrine

  • 43

    Ephedrine, Phenylephrine and Amphetamine which of these are indirect acting agonist

    Amphetamine

  • 44

    What is the Natural catecholamines:

    Epinephrine, Norepinephrine, Dopamine

  • 45

    What is the synthetic catecholamines:

    Isoproterenol

  • 46

    OH groups show highest potency in activating alpha or beta receptors

    High potency.

  • 47

    What are the rapid inactivation

    COMT (POSTSYNAPTICALLY), gut wall, MAO (intraneurally), liver, gut wall

  • 48

    Catecholamines presence of OH group at 3 & 4 pos. OH group at this pos also inc. polarity

    Inactivated by COMT

  • 49

    due to absence of substituent in alpha carbon

    Inactivated by MAO

  • 50

    presence of OH at β carbon.

    Direct acting agonist.

  • 51

    increase activity in beta receptors due to substituent in terminal amino group

    Non selective

  • 52

    NE (Levophed)

    IV

  • 53

    Epi (adrenalin)

    IV, SQ, Topical, Auto injector

  • 54

    Dopamine

    IV

  • 55

    Isoproterenol

    IV, Inhalation

  • 56

    potent vasoconstrictor & cardiac stimulant. and Gives positive inotropic & chronotropic effect

    Epinephrine.

  • 57

    Epinephrine (Adrenalin) Uses

    Anaphylactic shock, bronchospasm, hypersensitivity, glaucoma

  • 58

    First line inotropic agent in the management of septic shock- (SBP <90mmHg) due to systemic infection

    Norepinephrine

  • 59

    Norepinephrine also know as

    Levarterenol, Noradrenaline

  • 60

    Norepinephrine (Levophed) Uses

    Hypotension, Decongestant, infiltration anesthesia

  • 61

    immediate metabolic precursor of NE. Affinity to receptors:

    Dopamine.

  • 62

    Dopamine uses

    Septic shock, acute oliguric renal failure, Cardiogenic shock

  • 63

    Dec. activity in alpha receptor= bulky substituent in terminal amino group

    Isoproternol

  • 64

    Isoproterenol uses

    Asthma, COPD, Heart failure

  • 65

    What is the adverse effet oc Isoproterenol

    Cardiac arrhythmias, Tachyphylaxis

  • 66

    What is the precursor of catecholamines

    Tyrosine.

  • 67

    What ion is responsible for exit

    Calcium ion

  • 68

    Dilation of pupil

    Mydriasis.

  • 69

    What is the reponse to Alpha 1 receptors

    Erection.

  • 70

    A receptor that has the ability to increase your blood pressure / Vasoconstriction

    Alpha 1 receptors.

  • 71

    A type of blocker that has yhe ability to decrease your BP / Vasodilation

    Alpha 1 blocker.

  • 72

    What alpha 1 Synthesis

    Muscle contraction.

  • 73

    What do you call the space between pre synapse and post synapse

    Synaptic cleft.

  • 74

    Decrease catecholamines secretion

    NFE

  • 75

    What are the drugs that has NFE that decrease catecholamines secretion (norepinephrine and synthesis; Lowers blood pressure; Cure antihypertensive)

    Clonidine, Methyldopa

  • 76

    Inotropic agent for heart failure

    Beta 1 agonist

  • 77

    Increase the strength of cardiac contractions

    Inotropic

  • 78

    Increase the duration of heart muscle that lead to heart failure

    Chronotropism

  • 79

    Increase the conduct of cardiac cells

    Dromotropism

  • 80

    A Catecholamines receptors that has an ability to increase heart rate and increase stroke volume.

    Beta 1

  • 81

    A catecholamine receptors Juxtaglomerular cell if release its renin can increase blood pressure.

    Beta 1

  • 82

    Facilitate the sodium and water retention in the body

    Renin

  • 83

    A receptor that can decrease Blood pressure

    Alpha 2

  • 84

    A catecholamines receptor that can increase Blood pressure

    Beta 1

  • 85

    Used in mngt of bronchchi asthma and COPD

    Beta 2

  • 86

    A catecholamines receptors that found in autonomic nervous system.

    Dopamine 1

  • 87

    A catecholamines receptors that found in central nervous system.

    Dopamine 2-4

  • 88

    High dopamine level can cause

    Schizophrenia

  • 89

    Low dopamine level can cause

    Parkinsonism

  • 90

    Anti parkinsonism

    Dopamine 2 agonist

  • 91

    Antipsychotics drugs

    Dopamine 2 antagonist

  • Cell structure.

    Cell structure.

    Quinn Karylle Fuentes · 28問 · 2年前

    Cell structure.

    Cell structure.

    28問 • 2年前
    Quinn Karylle Fuentes

    Electrolytes and non electrolytes

    Electrolytes and non electrolytes

    Quinn Karylle Fuentes · 29問 · 2年前

    Electrolytes and non electrolytes

    Electrolytes and non electrolytes

    29問 • 2年前
    Quinn Karylle Fuentes

    MW

    MW

    Quinn Karylle Fuentes · 45問 · 2年前

    MW

    MW

    45問 • 2年前
    Quinn Karylle Fuentes

    POST LAB (EXP 4)

    POST LAB (EXP 4)

    Quinn Karylle Fuentes · 38問 · 2年前

    POST LAB (EXP 4)

    POST LAB (EXP 4)

    38問 • 2年前
    Quinn Karylle Fuentes

    Density and specific gravity

    Density and specific gravity

    Quinn Karylle Fuentes · 34問 · 2年前

    Density and specific gravity

    Density and specific gravity

    34問 • 2年前
    Quinn Karylle Fuentes

    FORCES OF ATTRACTION

    FORCES OF ATTRACTION

    Quinn Karylle Fuentes · 18問 · 2年前

    FORCES OF ATTRACTION

    FORCES OF ATTRACTION

    18問 • 2年前
    Quinn Karylle Fuentes

    Microbial growth

    Microbial growth

    Quinn Karylle Fuentes · 63問 · 2年前

    Microbial growth

    Microbial growth

    63問 • 2年前
    Quinn Karylle Fuentes

    Introduction.

    Introduction.

    Quinn Karylle Fuentes · 61問 · 2年前

    Introduction.

    Introduction.

    61問 • 2年前
    Quinn Karylle Fuentes

    Microbial control.

    Microbial control.

    Quinn Karylle Fuentes · 97問 · 2年前

    Microbial control.

    Microbial control.

    97問 • 2年前
    Quinn Karylle Fuentes

    States of matter

    States of matter

    Quinn Karylle Fuentes · 100問 · 2年前

    States of matter

    States of matter

    100問 • 2年前
    Quinn Karylle Fuentes

    Introduction.

    Introduction.

    Quinn Karylle Fuentes · 86問 · 2年前

    Introduction.

    Introduction.

    86問 • 2年前
    Quinn Karylle Fuentes

    Drug development.

    Drug development.

    Quinn Karylle Fuentes · 77問 · 2年前

    Drug development.

    Drug development.

    77問 • 2年前
    Quinn Karylle Fuentes

    CGMP

    CGMP

    Quinn Karylle Fuentes · 9問 · 2年前

    CGMP

    CGMP

    9問 • 2年前
    Quinn Karylle Fuentes

    Pharmaceutical ingredients.

    Pharmaceutical ingredients.

    Quinn Karylle Fuentes · 24問 · 2年前

    Pharmaceutical ingredients.

    Pharmaceutical ingredients.

    24問 • 2年前
    Quinn Karylle Fuentes

    Powdered & granules

    Powdered & granules

    Quinn Karylle Fuentes · 43問 · 2年前

    Powdered & granules

    Powdered & granules

    43問 • 2年前
    Quinn Karylle Fuentes

    Capsule.

    Capsule.

    Quinn Karylle Fuentes · 24問 · 2年前

    Capsule.

    Capsule.

    24問 • 2年前
    Quinn Karylle Fuentes

    Tablets.

    Tablets.

    Quinn Karylle Fuentes · 23問 · 2年前

    Tablets.

    Tablets.

    23問 • 2年前
    Quinn Karylle Fuentes

    Calculatiom of dose

    Calculatiom of dose

    Quinn Karylle Fuentes · 3回閲覧 · 66問 · 2年前

    Calculatiom of dose

    Calculatiom of dose

    3回閲覧 • 66問 • 2年前
    Quinn Karylle Fuentes

    Postlab 5&6

    Postlab 5&6

    Quinn Karylle Fuentes · 29問 · 2年前

    Postlab 5&6

    Postlab 5&6

    29問 • 2年前
    Quinn Karylle Fuentes

    COLLIGATIVE PROPERTIES.

    COLLIGATIVE PROPERTIES.

    Quinn Karylle Fuentes · 33問 · 2年前

    COLLIGATIVE PROPERTIES.

    COLLIGATIVE PROPERTIES.

    33問 • 2年前
    Quinn Karylle Fuentes

    SEMI SOLID

    SEMI SOLID

    Quinn Karylle Fuentes · 69問 · 2年前

    SEMI SOLID

    SEMI SOLID

    69問 • 2年前
    Quinn Karylle Fuentes

    Basic immunology

    Basic immunology

    Quinn Karylle Fuentes · 60問 · 2年前

    Basic immunology

    Basic immunology

    60問 • 2年前
    Quinn Karylle Fuentes

    Basic immunology (2)

    Basic immunology (2)

    Quinn Karylle Fuentes · 62問 · 2年前

    Basic immunology (2)

    Basic immunology (2)

    62問 • 2年前
    Quinn Karylle Fuentes

    Transdermal

    Transdermal

    Quinn Karylle Fuentes · 44問 · 2年前

    Transdermal

    Transdermal

    44問 • 2年前
    Quinn Karylle Fuentes

    Distribution.

    Distribution.

    Quinn Karylle Fuentes · 43問 · 2年前

    Distribution.

    Distribution.

    43問 • 2年前
    Quinn Karylle Fuentes

    Infectious disease.

    Infectious disease.

    Quinn Karylle Fuentes · 65問 · 2年前

    Infectious disease.

    Infectious disease.

    65問 • 2年前
    Quinn Karylle Fuentes

    Infectious diseases (2)

    Infectious diseases (2)

    Quinn Karylle Fuentes · 79問 · 2年前

    Infectious diseases (2)

    Infectious diseases (2)

    79問 • 2年前
    Quinn Karylle Fuentes

    Gram positive ( Bacteriology)

    Gram positive ( Bacteriology)

    Quinn Karylle Fuentes · 35問 · 2年前

    Gram positive ( Bacteriology)

    Gram positive ( Bacteriology)

    35問 • 2年前
    Quinn Karylle Fuentes

    All topic. ( Compressed.)

    All topic. ( Compressed.)

    Quinn Karylle Fuentes · 35問 · 2年前

    All topic. ( Compressed.)

    All topic. ( Compressed.)

    35問 • 2年前
    Quinn Karylle Fuentes

    All topic ( Compressed)

    All topic ( Compressed)

    Quinn Karylle Fuentes · 30問 · 2年前

    All topic ( Compressed)

    All topic ( Compressed)

    30問 • 2年前
    Quinn Karylle Fuentes

    All topics (compressed)

    All topics (compressed)

    Quinn Karylle Fuentes · 13問 · 2年前

    All topics (compressed)

    All topics (compressed)

    13問 • 2年前
    Quinn Karylle Fuentes

    Exercise 6 ; Isotonic solution.

    Exercise 6 ; Isotonic solution.

    Quinn Karylle Fuentes · 28問 · 2年前

    Exercise 6 ; Isotonic solution.

    Exercise 6 ; Isotonic solution.

    28問 • 2年前
    Quinn Karylle Fuentes

    Exercise 5 : Buffers.

    Exercise 5 : Buffers.

    Quinn Karylle Fuentes · 16問 · 2年前

    Exercise 5 : Buffers.

    Exercise 5 : Buffers.

    16問 • 2年前
    Quinn Karylle Fuentes

    Exercise 7 : Factors affecting solubility.

    Exercise 7 : Factors affecting solubility.

    Quinn Karylle Fuentes · 26問 · 2年前

    Exercise 7 : Factors affecting solubility.

    Exercise 7 : Factors affecting solubility.

    26問 • 2年前
    Quinn Karylle Fuentes

    Experiment 8: Disintegration.

    Experiment 8: Disintegration.

    Quinn Karylle Fuentes · 23問 · 2年前

    Experiment 8: Disintegration.

    Experiment 8: Disintegration.

    23問 • 2年前
    Quinn Karylle Fuentes

    Experiment 9 ; Interfacial phenomenon and surface tension.

    Experiment 9 ; Interfacial phenomenon and surface tension.

    Quinn Karylle Fuentes · 35問 · 2年前

    Experiment 9 ; Interfacial phenomenon and surface tension.

    Experiment 9 ; Interfacial phenomenon and surface tension.

    35問 • 2年前
    Quinn Karylle Fuentes

    EXP 9 : Aromatic ammonia spirit.

    EXP 9 : Aromatic ammonia spirit.

    Quinn Karylle Fuentes · 34問 · 2年前

    EXP 9 : Aromatic ammonia spirit.

    EXP 9 : Aromatic ammonia spirit.

    34問 • 2年前
    Quinn Karylle Fuentes

    EXP 10-11 : CAMPHOR WATER AND CINNAMON WATER.

    EXP 10-11 : CAMPHOR WATER AND CINNAMON WATER.

    Quinn Karylle Fuentes · 34問 · 2年前

    EXP 10-11 : CAMPHOR WATER AND CINNAMON WATER.

    EXP 10-11 : CAMPHOR WATER AND CINNAMON WATER.

    34問 • 2年前
    Quinn Karylle Fuentes

    EXP 12: ACACIA MUCILAGE

    EXP 12: ACACIA MUCILAGE

    Quinn Karylle Fuentes · 20問 · 2年前

    EXP 12: ACACIA MUCILAGE

    EXP 12: ACACIA MUCILAGE

    20問 • 2年前
    Quinn Karylle Fuentes

    EXP13&14 : Starch and Barrium sulfate.

    EXP13&14 : Starch and Barrium sulfate.

    Quinn Karylle Fuentes · 33問 · 2年前

    EXP13&14 : Starch and Barrium sulfate.

    EXP13&14 : Starch and Barrium sulfate.

    33問 • 2年前
    Quinn Karylle Fuentes

    EXP 15 : Liquid petroleum emulsion 1.0

    EXP 15 : Liquid petroleum emulsion 1.0

    Quinn Karylle Fuentes · 37問 · 2年前

    EXP 15 : Liquid petroleum emulsion 1.0

    EXP 15 : Liquid petroleum emulsion 1.0

    37問 • 2年前
    Quinn Karylle Fuentes

    EXP 15: Liquid petroleum emulsion 1.1

    EXP 15: Liquid petroleum emulsion 1.1

    Quinn Karylle Fuentes · 23問 · 2年前

    EXP 15: Liquid petroleum emulsion 1.1

    EXP 15: Liquid petroleum emulsion 1.1

    23問 • 2年前
    Quinn Karylle Fuentes

    Enterobacteriaceae

    Enterobacteriaceae

    Quinn Karylle Fuentes · 35問 · 2年前

    Enterobacteriaceae

    Enterobacteriaceae

    35問 • 2年前
    Quinn Karylle Fuentes

    Enterobacteriaceae.

    Enterobacteriaceae.

    Quinn Karylle Fuentes · 28問 · 2年前

    Enterobacteriaceae.

    Enterobacteriaceae.

    28問 • 2年前
    Quinn Karylle Fuentes

    LIQUID DOSAGE FORM 1.0

    LIQUID DOSAGE FORM 1.0

    Quinn Karylle Fuentes · 31問 · 2年前

    LIQUID DOSAGE FORM 1.0

    LIQUID DOSAGE FORM 1.0

    31問 • 2年前
    Quinn Karylle Fuentes

    Liquid dosage form

    Liquid dosage form

    Quinn Karylle Fuentes · 12問 · 2年前

    Liquid dosage form

    Liquid dosage form

    12問 • 2年前
    Quinn Karylle Fuentes

    MICROMERITICS 1.0

    MICROMERITICS 1.0

    Quinn Karylle Fuentes · 44問 · 2年前

    MICROMERITICS 1.0

    MICROMERITICS 1.0

    44問 • 2年前
    Quinn Karylle Fuentes

    EXP 7 : ENDOGENOUS AND EXOGENOUS MICROORGANISMS

    EXP 7 : ENDOGENOUS AND EXOGENOUS MICROORGANISMS

    Quinn Karylle Fuentes · 22問 · 2年前

    EXP 7 : ENDOGENOUS AND EXOGENOUS MICROORGANISMS

    EXP 7 : ENDOGENOUS AND EXOGENOUS MICROORGANISMS

    22問 • 2年前
    Quinn Karylle Fuentes

    EXP 8 : KIRBY-BAUER TECHNIQUE

    EXP 8 : KIRBY-BAUER TECHNIQUE

    Quinn Karylle Fuentes · 40問 · 2年前

    EXP 8 : KIRBY-BAUER TECHNIQUE

    EXP 8 : KIRBY-BAUER TECHNIQUE

    40問 • 2年前
    Quinn Karylle Fuentes

    EXP 9: STAPHYLOCOCCI

    EXP 9: STAPHYLOCOCCI

    Quinn Karylle Fuentes · 29問 · 2年前

    EXP 9: STAPHYLOCOCCI

    EXP 9: STAPHYLOCOCCI

    29問 • 2年前
    Quinn Karylle Fuentes

    Drug incompatibilities.

    Drug incompatibilities.

    Quinn Karylle Fuentes · 41問 · 2年前

    Drug incompatibilities.

    Drug incompatibilities.

    41問 • 2年前
    Quinn Karylle Fuentes

    Drug compatibilities.

    Drug compatibilities.

    Quinn Karylle Fuentes · 41問 · 2年前

    Drug compatibilities.

    Drug compatibilities.

    41問 • 2年前
    Quinn Karylle Fuentes

    BACTERIOLOGY 3

    BACTERIOLOGY 3

    Quinn Karylle Fuentes · 35問 · 2年前

    BACTERIOLOGY 3

    BACTERIOLOGY 3

    35問 • 2年前
    Quinn Karylle Fuentes

    BACTERIOLOGY 3

    BACTERIOLOGY 3

    Quinn Karylle Fuentes · 30問 · 2年前

    BACTERIOLOGY 3

    BACTERIOLOGY 3

    30問 • 2年前
    Quinn Karylle Fuentes

    SUSPENSION.

    SUSPENSION.

    Quinn Karylle Fuentes · 45問 · 2年前

    SUSPENSION.

    SUSPENSION.

    45問 • 2年前
    Quinn Karylle Fuentes

    Colloidal.

    Colloidal.

    Quinn Karylle Fuentes · 40問 · 2年前

    Colloidal.

    Colloidal.

    40問 • 2年前
    Quinn Karylle Fuentes

    BACTERIOLOGY 4 (Rickettsia)

    BACTERIOLOGY 4 (Rickettsia)

    Quinn Karylle Fuentes · 38問 · 2年前

    BACTERIOLOGY 4 (Rickettsia)

    BACTERIOLOGY 4 (Rickettsia)

    38問 • 2年前
    Quinn Karylle Fuentes

    BACTERIOLOGY.

    BACTERIOLOGY.

    Quinn Karylle Fuentes · 44問 · 2年前

    BACTERIOLOGY.

    BACTERIOLOGY.

    44問 • 2年前
    Quinn Karylle Fuentes

    Emulsion.

    Emulsion.

    Quinn Karylle Fuentes · 32問 · 2年前

    Emulsion.

    Emulsion.

    32問 • 2年前
    Quinn Karylle Fuentes

    EMULSION

    EMULSION

    Quinn Karylle Fuentes · 42問 · 2年前

    EMULSION

    EMULSION

    42問 • 2年前
    Quinn Karylle Fuentes

    MEDICAL RELATED PROBLEMS.

    MEDICAL RELATED PROBLEMS.

    Quinn Karylle Fuentes · 36問 · 2年前

    MEDICAL RELATED PROBLEMS.

    MEDICAL RELATED PROBLEMS.

    36問 • 2年前
    Quinn Karylle Fuentes

    MEDICATION RELATED PROBLEMS.

    MEDICATION RELATED PROBLEMS.

    Quinn Karylle Fuentes · 33問 · 2年前

    MEDICATION RELATED PROBLEMS.

    MEDICATION RELATED PROBLEMS.

    33問 • 2年前
    Quinn Karylle Fuentes

    Mycology.

    Mycology.

    Quinn Karylle Fuentes · 30問 · 2年前

    Mycology.

    Mycology.

    30問 • 2年前
    Quinn Karylle Fuentes

    Mycology 2.0

    Mycology 2.0

    Quinn Karylle Fuentes · 34問 · 2年前

    Mycology 2.0

    Mycology 2.0

    34問 • 2年前
    Quinn Karylle Fuentes

    m

    m

    Quinn Karylle Fuentes · 15問 · 2年前

    m

    m

    15問 • 2年前
    Quinn Karylle Fuentes

    ppr

    ppr

    Quinn Karylle Fuentes · 25問 · 2年前

    ppr

    ppr

    25問 • 2年前
    Quinn Karylle Fuentes

    MEDICAL DEVICES.

    MEDICAL DEVICES.

    Quinn Karylle Fuentes · 20問 · 2年前

    MEDICAL DEVICES.

    MEDICAL DEVICES.

    20問 • 2年前
    Quinn Karylle Fuentes

    Pharmacokinetics. (1.0)

    Pharmacokinetics. (1.0)

    Quinn Karylle Fuentes · 86問 · 2年前

    Pharmacokinetics. (1.0)

    Pharmacokinetics. (1.0)

    86問 • 2年前
    Quinn Karylle Fuentes

    Pharmacokinetics (1.1)

    Pharmacokinetics (1.1)

    Quinn Karylle Fuentes · 100問 · 2年前

    Pharmacokinetics (1.1)

    Pharmacokinetics (1.1)

    100問 • 2年前
    Quinn Karylle Fuentes

    Pharmacokinetics (1.2)

    Pharmacokinetics (1.2)

    Quinn Karylle Fuentes · 19問 · 2年前

    Pharmacokinetics (1.2)

    Pharmacokinetics (1.2)

    19問 • 2年前
    Quinn Karylle Fuentes

    Introduction.

    Introduction.

    Quinn Karylle Fuentes · 17問 · 2年前

    Introduction.

    Introduction.

    17問 • 2年前
    Quinn Karylle Fuentes

    Introduction of biochemistry

    Introduction of biochemistry

    Quinn Karylle Fuentes · 76問 · 2年前

    Introduction of biochemistry

    Introduction of biochemistry

    76問 • 2年前
    Quinn Karylle Fuentes

    Intro medicanal chemistry.

    Intro medicanal chemistry.

    Quinn Karylle Fuentes · 56問 · 2年前

    Intro medicanal chemistry.

    Intro medicanal chemistry.

    56問 • 2年前
    Quinn Karylle Fuentes

    Carbohydrates

    Carbohydrates

    Quinn Karylle Fuentes · 75問 · 2年前

    Carbohydrates

    Carbohydrates

    75問 • 2年前
    Quinn Karylle Fuentes

    Carbohydrates 1.1

    Carbohydrates 1.1

    Quinn Karylle Fuentes · 31問 · 2年前

    Carbohydrates 1.1

    Carbohydrates 1.1

    31問 • 2年前
    Quinn Karylle Fuentes

    Detect and quality variation.

    Detect and quality variation.

    Quinn Karylle Fuentes · 56問 · 2年前

    Detect and quality variation.

    Detect and quality variation.

    56問 • 2年前
    Quinn Karylle Fuentes

    INTRODUCTION

    INTRODUCTION

    Quinn Karylle Fuentes · 98問 · 2年前

    INTRODUCTION

    INTRODUCTION

    98問 • 2年前
    Quinn Karylle Fuentes

    lab (1-2)

    lab (1-2)

    Quinn Karylle Fuentes · 15問 · 2年前

    lab (1-2)

    lab (1-2)

    15問 • 2年前
    Quinn Karylle Fuentes

    lab 1-2

    lab 1-2

    Quinn Karylle Fuentes · 14問 · 2年前

    lab 1-2

    lab 1-2

    14問 • 2年前
    Quinn Karylle Fuentes

    Pharmaceutical chemistry.

    Pharmaceutical chemistry.

    Quinn Karylle Fuentes · 45問 · 2年前

    Pharmaceutical chemistry.

    Pharmaceutical chemistry.

    45問 • 2年前
    Quinn Karylle Fuentes

    Pharmaceutical chemistry 1.1

    Pharmaceutical chemistry 1.1

    Quinn Karylle Fuentes · 35問 · 2年前

    Pharmaceutical chemistry 1.1

    Pharmaceutical chemistry 1.1

    35問 • 2年前
    Quinn Karylle Fuentes

    Unit 3.

    Unit 3.

    Quinn Karylle Fuentes · 39問 · 2年前

    Unit 3.

    Unit 3.

    39問 • 2年前
    Quinn Karylle Fuentes

    Histamin and kinins

    Histamin and kinins

    Quinn Karylle Fuentes · 70問 · 2年前

    Histamin and kinins

    Histamin and kinins

    70問 • 2年前
    Quinn Karylle Fuentes

    PUD.

    PUD.

    Quinn Karylle Fuentes · 45問 · 2年前

    PUD.

    PUD.

    45問 • 2年前
    Quinn Karylle Fuentes

    ..

    ..

    Quinn Karylle Fuentes · 61問 · 2年前

    ..

    ..

    61問 • 2年前
    Quinn Karylle Fuentes

    Lipids.

    Lipids.

    Quinn Karylle Fuentes · 67問 · 2年前

    Lipids.

    Lipids.

    67問 • 2年前
    Quinn Karylle Fuentes

    lipids.

    lipids.

    Quinn Karylle Fuentes · 71問 · 2年前

    lipids.

    lipids.

    71問 • 2年前
    Quinn Karylle Fuentes

    LAB ✨

    LAB ✨

    Quinn Karylle Fuentes · 93問 · 2年前

    LAB ✨

    LAB ✨

    93問 • 2年前
    Quinn Karylle Fuentes

    Drug discovery.

    Drug discovery.

    Quinn Karylle Fuentes · 87問 · 2年前

    Drug discovery.

    Drug discovery.

    87問 • 2年前
    Quinn Karylle Fuentes

    disease of lipids.

    disease of lipids.

    Quinn Karylle Fuentes · 13問 · 2年前

    disease of lipids.

    disease of lipids.

    13問 • 2年前
    Quinn Karylle Fuentes

    Intro (identify structure)

    Intro (identify structure)

    Quinn Karylle Fuentes · 57問 · 2年前

    Intro (identify structure)

    Intro (identify structure)

    57問 • 2年前
    Quinn Karylle Fuentes

    Carbohydrates

    Carbohydrates

    Quinn Karylle Fuentes · 98問 · 2年前

    Carbohydrates

    Carbohydrates

    98問 • 2年前
    Quinn Karylle Fuentes

    Dynamic.

    Dynamic.

    Quinn Karylle Fuentes · 96問 · 2年前

    Dynamic.

    Dynamic.

    96問 • 2年前
    Quinn Karylle Fuentes

    Unit 1

    Unit 1

    Quinn Karylle Fuentes · 32問 · 2年前

    Unit 1

    Unit 1

    32問 • 2年前
    Quinn Karylle Fuentes

    問題一覧

  • 1

    What are the receptors of sympathetic

    Alpha, Beta, Dopamine

  • 2

    It has the property of adjusting in response to stressful situations such as trauma, fear, hypoglycemia, cold or exercise.

    Sympathetic nervous system.

  • 3

    The endogenous neurotransmitters contain three required structural features. What are those transmitter

    Catechol nucleus, a,b- hydroxy group, Nitrogen substituents.

  • 4

    Ortho hydroxybenzene

    Catechol 1& 2

  • 5

    Meta hydroxybenzene

    Resorcino 1 & 3

  • 6

    Para hydroxybenzene

    hydroquinone 1 & 4

  • 7

    The primary neurotransmitter of postganglionic sympathetic adrenergic nerves.

    Norepinephrine.

  • 8

    Synthesized inside nerve axon in the adrenal medulla and stored within vesicles. It is released by the nerve when an action potential travels down the nerve.

    Norepinephrine.

  • 9

    Receptors= Gq linked

    Alpha 1

  • 10

    Receptors= Gi linked

    Alpha 2

  • 11

    Exert negative feedback leading to decrease in the synthesis & release of NE

    Alpha 2

  • 12

    (+) inotropism, dromotropism, chronotropism

    Beta 1

  • 13

    The increase in cAMP levels in structures with beta2 receptors on them will lead to smooth muscle relaxation but skeletal muscle contraction.

    Beta 2

  • 14

    modulation of motor activity, behavior, mood & thought process Induce vomiting

    Dopamine 2-4

  • 15

    Gs linked

    Dopamine 1

  • 16

    like family receptors is coupled to the G protein Gi, which directly inhibits the formation of cAMP by inhibiting the enzyme adenylate cyclase

    Dopamine 2-4

  • 17

    Receptors of catecholamines are example of

    Type 2

  • 18

    Drugs that mimic the action of epinephrine or norepinephrine.

    Adrenoceptor Agonists

  • 19

    What are under Nonselective

    Epinephrine, Norepinephrine, Dopamine, Isoproterenol

  • 20

    What are under selective

    ALPHA 1 agonists, ALPHA 2 agonists, BETA 1 agonists, BETA 2 agonists, DOPAMINE 1 agonists

  • 21

    Binds directly to the receptor

    Direct acting.

  • 22

    Increase concentration of catecholamines in the synaptic cleft

    Indirect acting.

  • 23

    CNS centered effects

    Centrally acting

  • 24

    What are under increase release

    Tyramine, Ephedrine, Angiotensin II, Amphetamine

  • 25

    What are under inhibit re uptake

    TCAs, Cocaine, Reboxitine

  • 26

    What are under centrally acting

    Phenylpropanolamine, Amphetamine, Methylphenidate, Phentermine, Modafinil

  • 27

    considered as the parent compound from which sympathomimetic drugs are derived.

    Phenylethylamine.

  • 28

    consists of benzene ring with an ethylamine side chain

    Phenylethylamine.

  • 29

    consists of benzene ring with an ethylamine side chain

    Norepinephrine.

  • 30

    stimulates α1 , β1 and β2

    Epinephrine

  • 31

    stimulates β1 and β2

    Isoproterenol.

  • 32

    Methyl substitution on NE, yielding Epi, enhances activity at β2 receptors. ↑ β-receptor activity. The larger the substituent on the amino group, the lower the activity at α-receptor.

    Terminal amino group.

  • 33

    Substitution of OH group on benzene ring increases maximal α & β activity

    Benzene ring.

  • 34

    INACTIVATED BY COMT, cannot be given orally polar (Poor CNS penetration)

    With OH (at 3 and 4) catecholamines

  • 35

    not inactivated by COMT, can be given orally, non polar (CNS penetration)

    Without OH (at 3 and 4) non catecholamines

  • 36

    Dec. metabolism by monoamine oxidase (MAO).

    Alpha carbon.

  • 37

    Give example of alpha carbon.

    Ephedrine, Amphetamine

  • 38

    Substitution of OH group will become a direct-acting agonists. β-hydroxyl group.

    Beta carbon.

  • 39

    Ephedrine, Phenylephrine and Amphetamine which of these are non catecholamines

    All of them

  • 40

    Ephedrine, Phenylephrine and Amphetamine which of these are resistant to MAO metabolism

    Amphetamine, Ephedrine

  • 41

    Ephedrine, Phenylephrine and Amphetamine which of these are direct acting agonist

    Ephedrine, Phenylephrine

  • 42

    Ephedrine, Phenylephrine and Amphetamine which of these are direct acting agonist

    Ephedrine, Phenylephrine

  • 43

    Ephedrine, Phenylephrine and Amphetamine which of these are indirect acting agonist

    Amphetamine

  • 44

    What is the Natural catecholamines:

    Epinephrine, Norepinephrine, Dopamine

  • 45

    What is the synthetic catecholamines:

    Isoproterenol

  • 46

    OH groups show highest potency in activating alpha or beta receptors

    High potency.

  • 47

    What are the rapid inactivation

    COMT (POSTSYNAPTICALLY), gut wall, MAO (intraneurally), liver, gut wall

  • 48

    Catecholamines presence of OH group at 3 & 4 pos. OH group at this pos also inc. polarity

    Inactivated by COMT

  • 49

    due to absence of substituent in alpha carbon

    Inactivated by MAO

  • 50

    presence of OH at β carbon.

    Direct acting agonist.

  • 51

    increase activity in beta receptors due to substituent in terminal amino group

    Non selective

  • 52

    NE (Levophed)

    IV

  • 53

    Epi (adrenalin)

    IV, SQ, Topical, Auto injector

  • 54

    Dopamine

    IV

  • 55

    Isoproterenol

    IV, Inhalation

  • 56

    potent vasoconstrictor & cardiac stimulant. and Gives positive inotropic & chronotropic effect

    Epinephrine.

  • 57

    Epinephrine (Adrenalin) Uses

    Anaphylactic shock, bronchospasm, hypersensitivity, glaucoma

  • 58

    First line inotropic agent in the management of septic shock- (SBP <90mmHg) due to systemic infection

    Norepinephrine

  • 59

    Norepinephrine also know as

    Levarterenol, Noradrenaline

  • 60

    Norepinephrine (Levophed) Uses

    Hypotension, Decongestant, infiltration anesthesia

  • 61

    immediate metabolic precursor of NE. Affinity to receptors:

    Dopamine.

  • 62

    Dopamine uses

    Septic shock, acute oliguric renal failure, Cardiogenic shock

  • 63

    Dec. activity in alpha receptor= bulky substituent in terminal amino group

    Isoproternol

  • 64

    Isoproterenol uses

    Asthma, COPD, Heart failure

  • 65

    What is the adverse effet oc Isoproterenol

    Cardiac arrhythmias, Tachyphylaxis

  • 66

    What is the precursor of catecholamines

    Tyrosine.

  • 67

    What ion is responsible for exit

    Calcium ion

  • 68

    Dilation of pupil

    Mydriasis.

  • 69

    What is the reponse to Alpha 1 receptors

    Erection.

  • 70

    A receptor that has the ability to increase your blood pressure / Vasoconstriction

    Alpha 1 receptors.

  • 71

    A type of blocker that has yhe ability to decrease your BP / Vasodilation

    Alpha 1 blocker.

  • 72

    What alpha 1 Synthesis

    Muscle contraction.

  • 73

    What do you call the space between pre synapse and post synapse

    Synaptic cleft.

  • 74

    Decrease catecholamines secretion

    NFE

  • 75

    What are the drugs that has NFE that decrease catecholamines secretion (norepinephrine and synthesis; Lowers blood pressure; Cure antihypertensive)

    Clonidine, Methyldopa

  • 76

    Inotropic agent for heart failure

    Beta 1 agonist

  • 77

    Increase the strength of cardiac contractions

    Inotropic

  • 78

    Increase the duration of heart muscle that lead to heart failure

    Chronotropism

  • 79

    Increase the conduct of cardiac cells

    Dromotropism

  • 80

    A Catecholamines receptors that has an ability to increase heart rate and increase stroke volume.

    Beta 1

  • 81

    A catecholamine receptors Juxtaglomerular cell if release its renin can increase blood pressure.

    Beta 1

  • 82

    Facilitate the sodium and water retention in the body

    Renin

  • 83

    A receptor that can decrease Blood pressure

    Alpha 2

  • 84

    A catecholamines receptor that can increase Blood pressure

    Beta 1

  • 85

    Used in mngt of bronchchi asthma and COPD

    Beta 2

  • 86

    A catecholamines receptors that found in autonomic nervous system.

    Dopamine 1

  • 87

    A catecholamines receptors that found in central nervous system.

    Dopamine 2-4

  • 88

    High dopamine level can cause

    Schizophrenia

  • 89

    Low dopamine level can cause

    Parkinsonism

  • 90

    Anti parkinsonism

    Dopamine 2 agonist

  • 91

    Antipsychotics drugs

    Dopamine 2 antagonist